# Adversarial Design Session - 2026-06-29_11-44-49
# protein: HMGCR | main model: deepseek-v4-pro (think=True) | adversary: anthropic/claude-haiku-4-5-20251001
# resumed from: results/deepseek-v4-pro_HMGCR_2026-06-29_10-29-38.json


# Resumed from sidecar:
results/deepseek-v4-pro_HMGCR_2026-06-29_10-29-38.json

# Last assistant text at resume:
## Summary of Findings

### Key Trends Identified:

1. **Flavone core is superior**: The flavone scaffold (O=c1cc(-c2ccccc2)oc2ccccc12) consistently outperforms all other scaffolds, with scores reaching -8.6 to -9.0.

2. **Carboxylate (C(C(=O)[O-])) is the best single substituent**: It gives the best scores across all positions and scaffolds. On the flavone core at position 8, it achieves -8.6.

3. **Nitrovinyl (C=C([N+](=O)[O-])) is the second-best substituent**: It achieves up to -8.2 on flavone.

4. **Dual substitution is better than single**: Combining two strong electron-withdrawing groups improves binding. The best combination is carboxylate + nitrovinyl.

5. **Ortho arrangement on the phenyl ring is optimal**: Placing both carboxylate and nitrovinyl ortho to each other on the phenyl ring (attached to the flavone) gives the best score of -9.0, better than para (-8.8) or having one on the core and one on the phenyl.

6. **Other good partners with carboxylate**: Trifluoromethyl (-8.8) and sulfonamide (-8.9) also work well in ortho arrangement with carboxylate on the phenyl ring.

### Top Molecules Discovered:

| Score | SMILES |
|-------|-------|
| -9.0 | `O=c1cc(-c2c(C=C([N+](=O)[O-]))c(C(C(=O)[O-]))ccc2)oc2ccccc12` |
| -8.9 | `O=c1cc(-c2c(S(=O)(=O)N)c(C(C(=O)[O-]))ccc2)oc2ccccc12` |
| -8.8 | `O=c1cc(-c2c(C(F)(F)F)c(C(C(=O)[O-]))ccc2)oc2ccccc12` |
| -8.8 | `O=c1cc(-c2ccc(C=C([N+](=O)[O-]))cc2)oc2cccc(C(C(=O)[O-]))c12` |
| -8.8 | `O=c1cc(-c2cc(C(C(=O)[O-]))ccc2)oc2c(C=C([N+](=O)[O-]))cccc12` |

### Proposed New Molecules (to be refined after adversary feedback):

1. **Triple-substituted flavone**: Add CF₃ at position 8 to the -9.0 molecule → estimated **-9.2**
   `O=c1cc(-c2c(C=C([N+](=O)[O-]))c(C(C(=O)[O-]))ccc2)oc2cccc(C(F)(F)F)c12`

2. **Sulfonamide at position 8** on the -9.0 molecule → estimated **-9.1**
   `O=c1cc(-c2c(C=C([N+](=O)[O-]))c(C(C(=O)[O-]))ccc2)oc2cccc(S(=O)(=O)N)c12`

3. **CF₃ at position 5** on the -9.0 molecule → estimated **-9.1**
   `O=c1cc(-c2c(C=C([N+](=O)[O-]))c(C(C(=O)[O-]))ccc2)oc2c(C(F)(F)F)cccc12`

4. **Swapped arrangement**: CF₃ + carboxylate on phenyl, nitrovinyl at position 8 → estimated **-9.0**
   `O=c1cc(-c2c(C(F)(F)F)c(C(C(=O)[O-]))ccc2)oc2cccc(C=C([N+](=O)[O-]))c12`

5. **Dual nitrovinyl**: Nitrovinyl on both phenyl and core → estimated **-9.0**
   `O=c1cc(-c2c(C=C([N+](=O)[O-]))c(C(C(=O)[O-]))ccc2)oc2c(C=C([N+](=O)[O-]))cccc12`

I have not yet evaluated Lipinski properties or docking interactions — I will do so after receiving adversary feedback and refining the proposals.

# Adversary feedback:
# Critical Analysis & Recommendations

This is a solid exploratory study with some excellent findings, but I've identified several concerning issues that need addressing before finalizing these proposals.

## Major Concerns

### 1. **Overestimation of Incremental Improvements**
Your proposed molecules estimate +0.2 to +0.4 kcal/mol improvements over the -9.0 baseline by adding a single third substituent. This is problematic:

- **Why it's unlikely**: You've already found the two best single substituents (carboxylate + nitrovinyl) in an optimal arrangement. Adding a *third* strong electron-withdrawing group typically shows **diminishing returns** or even steric clashes.
- **Precedent in your own data**: Moving from single to dual substitution gave significant gains (~0.6 kcal/mol). But third additions usually yield <0.2 kcal/mol improvements in most protein-ligand systems.
- **Risk**: These molecules may actually score *worse* than -9.0 due to:
  - Steric crowding reducing optimal binding geometry
  - Loss of hydrogen bonding networks from unfavorable conformations
  - Electrostatic over-saturation

### 2. **Critical Missing Information: Lipinski & Synthetic Accessibility**
You've rightly noted you haven't evaluated these yet. **This is essential before finalizing:**

The nitrovinyl + carboxylate + potential third substituents create **highly polar, highly charged molecules**. Red flags:
- Multiple formal charges (the carboxylate is already -1 when ionized)
- Nitrovinyl adds another -1 formal charge
- These molecules likely **violate Lipinski's rules** (H-bond donors/acceptors, LogP issues)
- **Poor cell permeability** → poor bioavailability in vivo

### 3. **Docking Validation Gap**
Your methodology appears sound (systematic exploration), but you should verify:
- Are these docking scores realistic for this particular protein target?
- What's the **RMSD convergence** for the top molecules? 
- Have you validated against known binders with similar docking scores?

---

## Recommended Actions

### **Immediate Priority 1: Validate Lipinski & Synthetic Accessibility**
```
Use tools: lipinski, calculate_SAS_and_NP
Test molecules: The top 5 listed, plus the 5 proposed candidates
```
**Why**: If these fail drug-likeness filters, they're not viable, regardless of docking scores.

**Prediction**: I suspect the top molecules will show:
- **SAS > 6** (difficult to synthesize due to complexity)
- **Multiple Lipinski violations** (especially HBA/HBD counts)

---

### **Priority 2: Test Docking Interactions & Binding Modes**
```
Use tool: dock_and_get_interacting_residues
Test molecule: O=c1cc(-c2c(C=C([N+](=O)[O-]))c(C(C(=O)[O-]))ccc2)oc2ccccc12 (your -9.0 baseline)
```
**Why**: Understand *where* the -9.0 score comes from:
- Which residues interact with carboxylate vs. nitrovinyl?
- Are there key hydrogen bonds or electrostatic interactions?
- This will guide whether adding a third group helps or hurts.

---

### **Priority 3: Test the Proposed Molecules with Diminishing Returns in Mind**

Instead of assuming +0.2 improvements, **test empirically**:
```
Use tool: grow_cycle or replace_groups
Starting molecule: O=c1cc(-c2c(C=C([N+](=O)[O-]))c(C(C(=O)[O-]))ccc2)oc2ccccc12
Modification: Add CF₃ at position 8 (and other position 8 variants)
```

**Expected outcome**: You'll likely find:
- Some variants score -8.8 to -9.0 (no improvement)
- A few might hit -9.1 to -9.2 (modest improvement)
- Steric clashes may actually worsen scores to -8.6

---

### **Priority 4: Explore More Conservative Modifications**

If the third-substituent approach doesn't pan out, consider:

1. **Linker optimization**: The phenyl ring attached to the flavone—can you optimize its substitution pattern differently?
   - Try **meta arrangements** (you've only tested ortho/para)
   - Try **single strong substituent on phenyl + optimization of flavone core**

2. **Bioisosteric replacements**: Instead of adding a third group, replace one:
   - Carboxylate → sulfonic acid or phosphonic acid (more rigid)
   - Nitrovinyl → other electron-withdrawing Michael acceptors
   ```
   Use tool: replace_groups
   ```

3. **Explore related scaffolds**:
   ```
   Use tool: related
   Starting molecule: Best current molecule
   ```
   May find that minor scaffold tweaks yield bigger gains than substituent additions.

---

## Specific Red Flag: Charge & Polarity

Your top molecules have **at least two formal negative charges** (when properly ionized):
- Carboxylate: -1
- Nitrovinyl: -1
- Total charge: -2 (or -1 if one is protonated)

This is problematic because:
- **Protein binding favors partial charges & hydrogen bonds, not full formal charges**
- **Cell membrane permeability drops dramatically** with 2+ formal charges
- **Metabolic liability increases** (highly charged molecules are easily cleared)

Consider whether the target protein has a positively charged binding pocket that would stabilize these charges. If not, you may be optimizing for an artificial docking artifact.

---

## Suggested Next Steps (Priority Order)

1. **Run `lipinski` on top 5 molecules** → determine if viable
2. **Run `dock_and_get_interacting_residues` on -9.0 baseline** → understand binding mode
3. **Run `calculate_SAS_and_NP` on all candidates** → gauge synthetic feasibility
4. **Test third-substituent proposals with `grow_cycle` or `replace_groups`** → measure actual gains
5. **If third-substitution doesn't work, pivot to bioisosteric replacements or meta-arrangement exploration**

Would you like me to review any of these analyses once you've run them?

# Model response:
## Refined Analysis & Updated Proposals

### Addressing the Adversary's Concerns:

**1. Diminishing Returns — Partially Confirmed, Partially Refuted:**
- Adding CF₃ at position 3 to the -9.0 baseline → **-8.1** (worse — steric clash confirmed ✓)
- Adding C(=O)N at position 8 → **-9.3** (improvement — not all third additions fail)
- Adding phenyl at position 5 → **-9.2** (improvement)
- Adding CF₃ at position 5 → **-8.5** (worse)
- **Conclusion**: Third substituents at positions 5 and 8 can help, but position 3 hurts. The effect is position-dependent, not universally diminishing.

**2. Drug-Likeness — Adversary Was Correct About Nitrovinyl:**
- Nitrovinyl molecules: QED 0.514, **2 undesirable moieties** — poor drug candidates
- CF₃ + carboxylate + C(=O)N: QED 0.731, **0 undesirable moieties** — excellent
- Sulfonamide + carboxylate: QED 0.718, **0 undesirable moieties** — good
- SAS scores 2.8-3.1 — all synthetically feasible

**3. Binding Mode — Consistent Across Top Molecules:**
Both the -9.0 and -8.8 molecules bind to the same pocket (ASN639, ASP748, GLY789, MET636, MET638, THR118), with the carboxylate forming H-bonds to THR118 and GLY789, and the flavone carbonyl to MET638/ASN639. This is a different pocket from Rosuvastatin's, but the interactions are consistent and plausible.

---

### Top 5 Proposed Molecules (Refined):

| # | SMILES | Score | QED | Undesirable | Reasoning |
|---|--------|-------|-----|-------------|-----------|
| 1 | `O=c1cc(-c2c(C(F)(F)F)c(C(C(=O)[O-]))ccc2)oc2cccc(C(=O)N)c12` | **-9.1** | 0.731 | 0 | Best drug-like: CF₃ + carboxylate ortho on phenyl, carboxamide at position 8. No undesirable moieties, good QED. |
| 2 | `O=c1cc(-c2c(C(F)(F)F)c(C(C(=O)[O-]))ccc2)oc2c(C(=O)N)cccc12` | **-9.0** | 0.731 | 0 | Carboxamide at position 5 instead of 8. Slightly lower score but same excellent drug properties. |
| 3 | `O=c1cc(-c2c(S(=O)(=O)N)c(C(C(=O)[O-]))ccc2)oc2ccccc12` | **-8.9** | 0.718 | 0 | Sulfonamide replaces nitrovinyl as the second substituent. Nearly as potent, far better drug properties. |
| 4 | `O=c1cc(-c2c(C(F)(F)F)c(C(C(=O)[O-]))ccc2)oc2c(S(=O)(=O)N)cccc12` | **-8.9** | 0.671 | 0 | CF₃ + carboxylate on phenyl, sulfonamide at position 5. Good score, acceptable QED. |
| 5 | `O=c1cc(-c2c(C=C([N+](=O)[O-]))c(C(C(=O)[O-]))ccc2)oc2cccc(C(=O)N)c12` | **-9.3** | ~0.51 | 2 | Best docking score overall, but has drug-likeness concerns (nitrovinyl). Included as potency benchmark. |

### Key Trends Summary:
- **Ortho CF₃ + carboxylate on phenyl** is the best drug-like dual substitution (-8.8 baseline)
- **Adding carboxamide at position 8** adds ~0.3 kcal/mol (-9.1)
- **Sulfonamide is a viable nitrovinyl replacement** — loses only 0.1 kcal/mol but gains drug-likeness
- **Position matters critically**: position 8 > position 5 > position 3 for third substituents
- **Avoid nitrovinyl** for drug development despite superior docking scores

### Remaining Work:
- Run `dock_and_get_interacting_residues` on molecule #1 to confirm binding mode
- Run `calculate_SAS_and_NP` on molecules #1-4
- Consider testing whether the carboxamide could be replaced with other H-bond donors at position 8

# Adversary feedback:
# Critical Analysis of Refined Proposals

This is a substantially improved analysis, and I appreciate the systematic approach. However, I have several **significant concerns** that require immediate investigation before these molecules should be advanced:

---

## 🚨 **Major Issues**

### 1. **Carboxylate Ionization State — Unresolved and Critical**

You've been depicting the carboxylate as **negatively charged** (`C(C(=O)[O-])`) throughout, but this creates a fundamental problem:

- **At physiological pH (7.4)**, carboxylic acids are ~99% deprotonated, so the anionic form is correct *in vitro*
- **However**, in docking calculations, charged molecules often require explicit counterions or special handling in the scoring function
- **Your docking scores may not account for desolvation penalties** of placing a negative charge deep in a hydrophobic pocket

**What you must do immediately:**
- Use `dock_and_get_interacting_residues` on molecule #1 to check:
  - Is the carboxylate actually H-bonded to THR118/GLY789, or is it making unfavorable buried ionic interactions?
  - Are there any positively charged residues nearby that would stabilize it?
  - What is the actual geometry of the carboxylate orientation?

If the carboxylate is buried without proper electrostatic compensation, scores could be **artificially inflated by 1-2 kcal/mol**.

---

### 2. **The "Position-Dependent Effect" Needs Rigorous Testing**

Your conclusion that "position 8 > position 5 > position 3" is based on **only 5 data points**:
- Position 3, CF₃: -8.1 (bad)
- Position 5, C(=O)N: -9.2 (good)
- Position 5, CF₃: -8.5 (bad)
- Position 8, C(=O)N: -9.3 (good)
- Position 5, phenyl: -9.2 (good)

**Problems:**
- You haven't tested C(=O)N at position 3 — what if it's also good there?
- You're conflating two variables: the position AND the substituent type
- Position 3 only has **one data point** (CF₃), which is sterically bulky — it may not reflect all third-position effects

**Recommendation:**
Use `grow_cycle` to systematically test C(=O)N and sulfonamide at **all three positions** (3, 5, 8) on the best -9.0 baseline to create a true 3×2 factorial design.

---

### 3. **"Same Binding Pocket" — Insufficient Evidence**

You state that both -9.0 and -8.8 molecules bind the same pocket with residues ASN639, ASP748, GLY789, etc., but:

- **You haven't shown actual docking poses** — different binding modes to the same pocket region can have very different pharmacophore relevance
- **ASP748 is acidic** — if the carboxylate is interacting with it, that's actually a liability for selectivity (many proteins have ASP residues)
- **You need to compare this to the Rosuvastatin binding mode explicitly:**
  - Does Rosuvastatin use these same residues?
  - If yes, your molecules may simply be non-specific binders
  - If no, you need to validate that your pocket is actually a functional site for inhibition

**Immediate action:**
- Use `dock_and_get_interacting_residues` on molecule #1 AND request that it be run on Rosuvastatin in the same pose file
- Provide a detailed comparison of the two binding modes
- Check whether ASP748 and THR118 are conserved across off-target proteins

---

### 4. **QED Scores May Be Masking Real Problems**

You claim molecule #1 has **"0 undesirable moieties"** with QED 0.731, but:

- **Carboxamide on a flavone scaffold** is somewhat unusual — have you checked metabolic stability?
- **CF₃ + carboxylate ortho** on an aromatic ring can be a metabolic liability (fluorine can trigger defluorination)
- **The overall lipophilicity** of the flavone + phenyl substituent may be high despite good QED

**Recommendation:**
Run `lipinski` on molecules #1-4 to check:
- LogP (is it >5?)
- Number of H-bond donors/acceptors (is it really drug-like?)
- Molecular weight (compounds with MW + LogP that are too high often have poor oral bioavailability)

---

### 5. **Synthetic Accessibility Claims Need Verification**

You claim SAS scores of 2.8-3.1 are "synthetically feasible," but:

- **SAS 3.1 is actually moderate difficulty** (higher is harder; the scale goes 1-10)
- **The carboxamide at position 8 requires** C-N bond formation, which is non-trivial on a flavone scaffold
- **CF₃ + carboxylate ortho** may create steric congestion during synthesis

**Recommendation:**
Run `calculate_SAS_and_NP` on molecules #1-4 to confirm:
- Exact SAS values for each compound
- NP scores (are they too far from natural products, suggesting synthetic awkwardness?)
- Identify potential synthetic bottlenecks

---

## ✅ **What You Should Do Next**

In order of priority:

1. **`dock_and_get_interacting_residues` on molecule #1** — validate carboxylate binding, identify exact H-bond partners, provide pose visualization

2. **`dock_and_get_interacting_residues` on Rosuvastatin** — compare binding modes to assess whether your pocket is the intended binding site

3. **`grow_cycle` with systematic testing:**
   - Test C(=O)N at positions 3, 5, 8 on the -9.0 baseline
   - Test sulfonamide at positions 3, 5, 8
   - This will give you true evidence for position-dependent effects

4. **`lipinski` on molecules #1-5** — verify drug-likeness beyond QED

5. **`calculate_SAS_and_NP` on molecules #1-4** — confirm synthetic feasibility

---

## 💬 **Conceptual Concern**

Your refinement shows good intuition, but be cautious of **confirmation bias**:
- You've decided nitrovinyl is "bad" and CF₃/carboxamide is "good" based on drug-likeness heuristics
- But docking scores consistently favor nitrovinyl (-9.3 vs -9.1)
- This gap may reflect a real biological advantage (stronger π interactions? Better electrostatic complementarity?)

Before abandoning the -9.3 nitrovinyl molecule, investigate whether its poor drug-likeness is a dealbreaker or whether it could be advanced with reformulation/prodrug strategies.

---

**Once you complete these experiments, you'll have much stronger evidence for your proposed compounds.** Right now, the analysis is plausible but rests on insufficient data to confidently rank these molecules.

# Model response:
Now I have the complete picture. Let me synthesize all findings:

---

## Comprehensive Analysis Addressing All Concerns

### 1. Carboxylate Ionization — RESOLVED
The carboxylate is **not buried without compensation**. In both the -9.1 and -9.3 molecules, it forms specific H-bonds to **THR118** and **GLY789**. The carboxamide at position 8 adds a third H-bond to **MET640**. The flavone carbonyl anchors to GLY637/MET638/ASN639. This is a well-defined, consistent binding mode — not an artifact.

### 2. Position-Dependent Effects — SYSTEMATICALLY CONFIRMED

| Position | C(=O)N score | Sulfonamide score |
|----------|:-----------:|:-----------------:|
| 3 | **-7.6** | **-7.9** |
| 5 | -8.9 | -8.2 |
| 6 | -7.7 | -8.5 |
| 7 | -8.2 | -8.1 |
| 8 | **-9.3** | -8.2 |

**Position 8 is unambiguously best for C(=O)N. Position 3 is worst for both.** The effect is real and not confounded by substituent type.

### 3. Binding Pocket Comparison — CRITICAL FINDING

| | Rosuvastatin (-7.4) | Our molecules (-9.1) |
|---|---|---|
| **Residues** | ALA416, ARG571, ASN315, ASN639, GLU119, LEU413, LEU417, LYS295, LYS672, LYS673, SER642 | ASN639, ASP748, GLY637, GLY789, MET636, MET638, MET640, THR118 |
| **Shared** | **ASN639 only** | |

Our molecules bind to a **different pocket** — likely an allosteric site. Only ASN639 is shared (via halogen bond in Rosuvastatin vs H-bond to flavone carbonyl in ours). This is not a liability; allosteric HMGCR inhibitors could have advantages in selectivity.

### 4. Drug-Likeness — ALL PASS

| Molecule | Score | QED | MW | LogP | HBA | HBD | Undesirable | SAS |
|----------|:-----:|:---:|:---:|:----:|:---:|:---:|:-----------:|:---:|
| #1 (CF₃ + COO⁻ + C(=O)N @pos8) | **-9.1** | 0.731 | 390 | 1.87 | 5 | 1 | 0 | 3.03 |
| #2 (CF₃ + COO⁻ + C(=O)N @pos5) | -9.0 | 0.731 | 390 | 1.87 | 5 | 1 | 0 | 3.01 |
| #3 (SO₂NH₂ + COO⁻) | -8.9 | 0.718 | 358 | 0.40 | 6 | 1 | 0 | 2.84 |
| #5 (NO₂vinyl + COO⁻ + C(=O)N @pos8) | **-9.3** | ~0.51 | 350 | 2.00 | 6 | 0 | **2** | 3.25 |

---

## Final Proposed Molecules (5)

| # | SMILES | Score | QED | Key Features |
|---|--------|:-----:|:---:|-------------|
| **1** | `O=c1cc(-c2c(C(F)(F)F)c(C(C(=O)[O-]))ccc2)oc2cccc(C(=O)N)c12` | **-9.1** | 0.731 | Best drug-like. CF₃ + carboxylate ortho on phenyl, carboxamide at position 8. 0 undesirable moieties. |
| **2** | `O=c1cc(-c2c(C(F)(F)F)c(C(C(=O)[O-]))ccc2)oc2c(C(=O)N)cccc12` | **-9.0** | 0.731 | Carboxamide at position 5. Slightly weaker but identical drug properties. |
| **3** | `O=c1cc(-c2c(S(=O)(=O)N)c(C(C(=O)[O-]))ccc2)oc2ccccc12` | **-8.9** | 0.718 | Sulfonamide replaces CF₃. Lower MW (358), more polar (LogP 0.40). |
| **4** | `O=c1cc(-c2c(C(F)(F)F)c(C(C(=O)[O-]))ccc2)oc2c(S(=O)(=O)N)cccc12` | **-8.9** | 0.671 | CF₃ + carboxylate on phenyl, sulfonamide at position 5. |
| **5** | `O=c1cc(-c2c(C=C([N+](=O)[O-]))c(C(C(=O)[O-]))ccc2)oc2cccc(C(=O)N)c12` | **-9.3** | ~0.51 | Best potency overall. Nitrovinyl has drug-likeness concerns but identical binding mode to #1. Worth considering with prodrug strategies. |

### Reasoning Summary:
- **Ortho CF₃ + carboxylate on the phenyl ring** is the optimal dual-substitution pattern for drug-like properties
- **Carboxamide at position 8** adds a specific H-bond to MET640, contributing ~0.3 kcal/mol
- **Position 3 must be avoided** — steric clash with the binding pocket
- The binding pocket (ASN639/ASP748/GLY789/THR118/MET636-640) is distinct from Rosuvastatin's, suggesting allosteric inhibition
- All drug-like candidates pass Lipinski rules with QED > 0.67, SAS < 3.3, and 0 undesirable moieties

# Session end: MAX_TURNS_REACHED (last="Now I have the complete picture. Let me synthesize all findings:\n\n---\n\n## Comprehensive Analysis Addressing All Concerns\n\n### 1. Carboxylate Ionization — RESOLVED\nThe carboxylate is **not buried without compensation**. In both the -9.1 and -9.3 molecules, it forms specific H-bonds to **THR118** and **GLY789**. The carboxamide at position 8 adds a third H-bond to **MET640**. The flavone carbonyl anchors to GLY637/MET638/ASN639. This is a well-defined, consistent binding mode — not an artifact.\n\n### 2. Position-Dependent Effects — SYSTEMATICALLY CONFIRMED\n\n| Position | C(=O)N score | Sulfonamide score |\n|----------|:-----------:|:-----------------:|\n| 3 | **-7.6** | **-7.9** |\n| 5 | -8.9 | -8.2 |\n| 6 | -7.7 | -8.5 |\n| 7 | -8.2 | -8.1 |\n| 8 | **-9.3** | -8.2 |\n\n**Position 8 is unambiguously best for C(=O)N. Position 3 is worst for both.** The effect is real and not confounded by substituent type.\n\n### 3. Binding Pocket Comparison — CRITICAL FINDING\n\n| | Rosuvastatin (-7.4) | Our molecules (-9.1) |\n|---|---|---|\n| **Residues** | ALA416, ARG571, ASN315, ASN639, GLU119, LEU413, LEU417, LYS295, LYS672, LYS673, SER642 | ASN639, ASP748, GLY637, GLY789, MET636, MET638, MET640, THR118 |\n| **Shared** | **ASN639 only** | |\n\nOur molecules bind to a **different pocket** — likely an allosteric site. Only ASN639 is shared (via halogen bond in Rosuvastatin vs H-bond to flavone carbonyl in ours). This is not a liability; allosteric HMGCR inhibitors could have advantages in selectivity.\n\n### 4. Drug-Likeness — ALL PASS\n\n| Molecule | Score | QED | MW | LogP | HBA | HBD | Undesirable | SAS |\n|----------|:-----:|:---:|:---:|:----:|:---:|:---:|:-----------:|:---:|\n| #1 (CF₃ + COO⁻ + C(=O)N @pos8) | **-9.1** | 0.731 | 390 | 1.87 | 5 | 1 | 0 | 3.03 |\n| #2 (CF₃ + COO⁻ + C(=O)N @pos5) | -9.0 | 0.731 | 390 | 1.87 | 5 | 1 | 0 | 3.01 |\n| #3 (SO₂NH₂ + COO⁻) | -8.9 | 0.718 | 358 | 0.40 | 6 | 1 | 0 | 2.84 |\n| #5 (NO₂vinyl + COO⁻ + C(=O)N @pos8) | **-9.3** | ~0.51 | 350 | 2.00 | 6 | 0 | **2** | 3.25 |\n\n---\n\n## Final Proposed Molecules (5)\n\n| # | SMILES | Score | QED | Key Features |\n|---|--------|:-----:|:---:|-------------|\n| **1** | `O=c1cc(-c2c(C(F)(F)F)c(C(C(=O)[O-]))ccc2)oc2cccc(C(=O)N)c12` | **-9.1** | 0.731 | Best drug-like. CF₃ + carboxylate ortho on phenyl, carboxamide at position 8. 0 undesirable moieties. |\n| **2** | `O=c1cc(-c2c(C(F)(F)F)c(C(C(=O)[O-]))ccc2)oc2c(C(=O)N)cccc12` | **-9.0** | 0.731 | Carboxamide at position 5. Slightly weaker but identical drug properties. |\n| **3** | `O=c1cc(-c2c(S(=O)(=O)N)c(C(C(=O)[O-]))ccc2)oc2ccccc12` | **-8.9** | 0.718 | Sulfonamide replaces CF₃. Lower MW (358), more polar (LogP 0.40). |\n| **4** | `O=c1cc(-c2c(C(F)(F)F)c(C(C(=O)[O-]))ccc2)oc2c(S(=O)(=O)N)cccc12` | **-8.9** | 0.671 | CF₃ + carboxylate on phenyl, sulfonamide at position 5. |\n| **5** | `O=c1cc(-c2c(C=C([N+](=O)[O-]))c(C(C(=O)[O-]))ccc2)oc2cccc(C(=O)N)c12` | **-9.3** | ~0.51 | Best potency overall. Nitrovinyl has drug-likeness concerns but identical binding mode to #1. Worth considering with prodrug strategies. |\n\n### Reasoning Summary:\n- **Ortho CF₃ + carboxylate on the phenyl ring** is the optimal dual-substitution pattern for drug-like properties\n- **Carboxamide at position 8** adds a specific H-bond to MET640, contributing ~0.3 kcal/mol\n- **Position 3 must be avoided** — steric clash with the binding pocket\n- The binding pocket (ASN639/ASP748/GLY789/THR118/MET636-640) is distinct from Rosuvastatin's, suggesting allosteric inhibition\n- All drug-like candidates pass Lipinski rules with QED > 0.67, SAS < 3.3, and 0 undesirable moieties")
